IND granted for FAP targeting therapeutic in SOFIE partnership
Dulles, VA – January 17, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
SOFIE granted IND for 18F-FAPI in Phase 2 study
Dulles, VA – November 29, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
Focus on FAPI Newsletter – October 2022
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
We are excited to launch our FAPI newsletter […]
SOFIE submits IND for [18F]-FAPI-74 in Phase 2 study of Gastrointestinal Cancers
Dulles, VA – October 31, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
First Patient Imaged in SOFIE’s FAPI Phase II Trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged […]
![Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74](https://sofie.com/wp-content/uploads/2022/09/image-3.png)
Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74
Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, […]
![Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types](https://sofie.com/wp-content/uploads/2022/09/image-1.png)
Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types GalleryAutomated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra